@article{424a17cc46ba4e3e863d7e5c801baced,
title = "The efficacy of rituximab in high-risk renal transplant recipients",
abstract = "Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.",
keywords = "End-stage renal disease, Immunosuppression, Kidney transplantation",
author = "Motoo Araki and Koichiro Wada and Yosuke Mitsui and Risa Kubota and Takashi Yoshioka and Yuichi Ariyoshi and Yasuyuki Kobayashi and Masashi Kitagawa and Katsuyuki Tanabe and Hiroshi Sugiyama and Jun Wada and Masami Watanabe and Toyohiko Watanabe and Katsuyuki Hotta and Yasutomo Nasu",
note = "Funding Information: The authors wish to acknowledge and thank the coordinators and all other investigators who have contributed to this study. This protocol has been written with support from the Center for Innovative Clinical Medicine, Okayama University Hospital. Publisher Copyright: {\textcopyright} 2016 by Okayama University Medical School.",
year = "2016",
language = "English",
volume = "70",
pages = "295--298",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",
}